abstract |
The present invention relates to new 6-substituted 1,2,4-triazolo [4,3-b] pyridazines of formula (I), which are Rev-Erb agonists. Such compounds and pharmaceutical compositions including them are suitable agents for treating any disease in which Rev-Erb activation has a therapeutic effect, for example, in inflammatory and circadian rhythm disorders or cardiometabolic diseases. |